We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine

This study is currently recruiting participants.
Verified December 2015 by Yong Min Ahn, Seoul National University Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT01654640
First Posted: August 1, 2012
Last Update Posted: December 8, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Daewoong Pharmaceutical Co. LTD.
Information provided by (Responsible Party):
Yong Min Ahn, Seoul National University Hospital
  Purpose
The purpose of this study is the evaluation of effect of metformin on obesity and metabolic disturbance in patients taking clozapine.

Condition Intervention Phase
Schizophrenia Drug: Metformin Drug: Placebo (for metformin) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 4 Study of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Yong Min Ahn, Seoul National University Hospital:

Primary Outcome Measures:
  • change of weight [ Time Frame: baseline, 12 weeks, 24 weeks ]
    change of weight after 12-week, 24-week. calculation; (weight of 12-week - weight of baseline)/baseline weight (weight of 24-week - weight of baseline)/baseline weight


Secondary Outcome Measures:
  • Positive and Negative Symptom Scale(PANSS) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • MADRS(montgomery asberg depression rating scale) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • Clinical Global Impression-severity(CGI-S) [ Time Frame: baseline, 6 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • Clinical Global Impression-improvement(CGI-I) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • Beck's Depression Inventory(BDI) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • Liverpool University Neuroleptic Side Effect Rating Scale(LUNSERS) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • World Health Organization Quality of Life-BREF (WHOQOL-BREF) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • Short form(36) Health survey (SF-36) [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 1-week, 4-week, 12-week, 24-week(end-point)

  • abdominal fat amount CT [ Time Frame: baseline, 12 weeks, 24 weeks ]
    baseline, 12-week, 24-week

  • change of prevalence of metabolic syndrome [ Time Frame: baseline, 12 weeks, 24 weeks ]
    waist circumference, blood pressure cholesterol,triglyceride, HDL-cholesterol,fasting glucose
Estimated Enrollment: 30
Study Start Date: July 2012
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metformin group
Metformin 500mg 1 tablet p.o. bid
 Drug: Metformin
metformin 500mg p.o. bid for 24 weeks
Other Name: Diabex
Placebo Comparator: Placebo group
1 tablet p.o. bid
 Drug: Placebo (for metformin)
placebo 1T bid
Other Name: placebo

Detailed Description:
In this study, the investigators are going to examine the effect of metformin on obesity and metabolic disturbance in patients with schizophrenia who have taken clozapine.The metformin 500mg will be administrated per oral twice a day for 24 weeks and for control group, placebo will be given same route and process.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 18 ~ 65
  • Patient with schizophrenia according to DSM-IV criteria
  • Patient have signed on the informed consent, and well understood the objective and procedure of this study.
  • Patient taking clozapine 3months or more
  • Patient increased in weight more than 10 % of that of before antipsychotics use

Exclusion Criteria:

  • Patient taking other antipsychotics with clozapine
  • Patient in treatment of diabetes
  • Patient in treatment of dyslipidemia
  • Allergy or hypersensitivity to metformin
  • Pregnant or breast-feeding female patient.
  • Patient with severe medical condition
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01654640


Contacts
Contact: Hyun Jeong Lee, MD hjlee.np@gmail.com

Locations
Korea, Republic of
Seoul National University Hospital Not yet recruiting
Seoul, Korea, Republic of
Contact: Hyun Jeong Lee, MD       hjlee.np@gmail.com   
Principal Investigator: Yong Min Ahn, MD, PhD         
Sub-Investigator: Hyun Jeong Lee, MD         
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of
Principal Investigator: Yong Min Ahn, MD., PhD.         
Sponsors and Collaborators
Seoul National University Hospital
Daewoong Pharmaceutical Co. LTD.
Investigators
Principal Investigator: Yong Min Ahn, MD, PhD Seoul National University Hospital
  More Information

Additional Information:
study site  This link exits the ClinicalTrials.gov site

Responsible Party: Yong Min Ahn, professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01654640     History of Changes
Other Study ID Numbers: DW_Metformin
First Submitted: July 16, 2012
First Posted: August 1, 2012
Last Update Posted: December 8, 2015
Last Verified: December 2015

Keywords provided by Yong Min Ahn, Seoul National University Hospital:
schizophrenia
obesity
clozapine
metformin

Additional relevant MeSH terms:
Obesity
Schizophrenia
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Metformin
Clozapine
Hypoglycemic Agents
 Physiological Effects of Drugs
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
GABA Antagonists
GABA Agents